|
epidemiology |
22 |
|
systemic lupus erythematosus |
20 |
|
genome-wide association study |
19 |
|
hong kong |
18 |
|
asian continental ancestry group - genetics |
15 |
|
allergy |
14 |
|
chinese |
14 |
|
genetic predisposition to disease |
14 |
|
lupus nephritis |
13 |
|
prevalence |
13 |
|
antigens, cd3 - genetics |
11 |
|
asian |
11 |
|
association |
11 |
|
cd247 |
11 |
|
covid-19 |
11 |
|
gwas |
11 |
|
lupus erythematosus, systemic - enzymology - genetics |
11 |
|
lupus erythematosus, systemic - genetics - immunology |
11 |
|
model |
11 |
|
all-cause pneumonia |
10 |
|
drug |
10 |
|
herd immunity |
10 |
|
hypersensitivity |
10 |
|
interrupted time series analysis |
10 |
|
intracellular signaling peptides and proteins - genetics |
10 |
|
pneumococcal conjugate vaccines |
10 |
|
population-based electronic health records |
10 |
|
bnt162b2 |
9 |
|
coronavac |
9 |
|
omicron |
9 |
|
stroke |
9 |
|
waning vaccine effectiveness |
9 |
|
prediction |
8 |
|
risk assessment |
8 |
|
spondyloarthritis |
8 |
|
anaphylaxis |
7 |
|
antibodies, antinuclear - blood |
7 |
|
autoantibodies |
7 |
|
autoantibodies - blood |
7 |
|
carbapenemase-producing enterobacteriaceae |
7 |
|
carriage |
7 |
|
cluster analysis |
7 |
|
genome sequencing |
7 |
|
genomic diversity |
7 |
|
hong kong - epidemiology |
7 |
|
hong kong genome project |
7 |
|
long read genome sequencing |
7 |
|
lupus erythematosus |
7 |
|
lupus erythematosus, systemic - ethnology - immunology |
7 |
|
mortality |
7 |
|
multivariate analysis |
7 |
|
nested case-control study |
7 |
|
population-based genome project |
7 |
|
precision medicine |
7 |
|
prophylaxis |
7 |
|
rare disease |
7 |
|
risk factor |
7 |
|
short read genome sequencing |
7 |
|
systemic |
7 |
|
cardiovascular event |
6 |
|
cerebrovascular event |
6 |
|
immunodeficiency |
6 |
|
myocardial infarction |
6 |
|
asia pacific |
5 |
|
diagnosis |
5 |
|
genetics |
5 |
|
immunization |
5 |
|
incidence |
5 |
|
inflammation |
5 |
|
penicillin |
5 |
|
penicillins |
5 |
|
prevention |
5 |
|
public health |
5 |
|
quality of life |
5 |
|
rheumatology |
5 |
|
subphenotype |
5 |
|
t follicular helper |
5 |
|
urticaria |
5 |
|
allergy centre |
4 |
|
allergy services |
4 |
|
angioedema |
4 |
|
ankylosing spondylitis |
4 |
|
antirheumatic agents |
4 |
|
asas criteria |
4 |
|
axial spondyloarthritis |
4 |
|
basophil activation test |
4 |
|
cervical cancer |
4 |
|
chronic |
4 |
|
corner inflammatory lesion |
4 |
|
fungal |
4 |
|
hereditary angioedema |
4 |
|
modified new york criteria |
4 |
|
mri |
4 |
|
pneumonia |
4 |
|
risk |
4 |
|
safety |
4 |
|
training |
4 |
|
uveitis |
4 |
|
age |
3 |
|
antibiotics |
3 |
|
apparent weighted coefficient |
3 |
|
ascending |
3 |
|
autoimmune disorders |
3 |
|
batf |
3 |
|
beta-lactam |
3 |
|
bibliometric |
3 |
|
calycosin |
3 |
|
cardiovascular diseases |
3 |
|
caveolin-1 |
3 |
|
clinical trial |
3 |
|
cp: immunology |
3 |
|
crispr/cas9 |
3 |
|
cu-q2ol |
3 |
|
diffusion weighted imaging |
3 |
|
drug allergy |
3 |
|
education |
3 |
|
expanded potential |
3 |
|
fenofibrate |
3 |
|
gain of function |
3 |
|
garadacimab |
3 |
|
gene editing |
3 |
|
guidelines |
3 |
|
herpes zoster |
3 |
|
humanized |
3 |
|
icos |
3 |
|
immunocompromised |
3 |
|
inborn errors of immunity |
3 |
|
interleukin-17 |
3 |
|
janus activating kinase (jak) inhibitor |
3 |
|
lanadelumab |
3 |
|
magnetic resonance imaging |
3 |
|
marginal zone b |
3 |
|
mediation analysis |
3 |
|
mekk3 |
3 |
|
metabolism |
3 |
|
methotrexate |
3 |
|
migration |
3 |
|
mouse model |
3 |
|
multidisciplinary |
3 |
|
neutralization |
3 |
|
patient-reported outcome |
3 |
|
patient-reported outcome measures |
3 |
|
peripheral vascular diseases |
3 |
|
personalized |
3 |
|
phosphorylation |
3 |
|
ppar |
3 |
|
predictors |
3 |
|
quality-of-life |
3 |
|
research |
3 |
|
signal transducer and activator of transcription 1 (stat1) |
3 |
|
sjogren |
3 |
|
sjögren disease |
3 |
|
sjögren syndrome |
3 |
|
sjögren's disease |
3 |
|
sjögren’s disease |
3 |
|
sjögren’s syndrome |
3 |
|
stem cell |
3 |
|
sting |
3 |
|
trends |
3 |
|
type i ifn |
3 |
|
vaccination |
3 |
|
vaccine |
3 |
|
validation |
3 |
|
varicella-zoster virus |
3 |
|
work productivity |
3 |
|
accessibility |
2 |
|
acinetobacter |
2 |
|
acute generalized exanthematous pustulosis |
2 |
|
adrenaline |
2 |
|
adrenaline autoinjector |
2 |
|
adult |
2 |
|
allergens and epitopes |
2 |
|
anti-bacterial agents |
2 |
|
arthrocentesis |
2 |
|
asia |
2 |
|
atopic dermatitis |
2 |
|
autoantibody clusters |
2 |
|
autoinjector |
2 |
|
beta-lactams |
2 |
|
c1 inhibitor |
2 |
|
c6 |
2 |
|
carbapenem resistance |
2 |
|
case report |
2 |
|
chemokine (c–c motif) ligand 2 (ccl-2) |
2 |
|
chronic rhinosinusitis |
2 |
|
chronic spontaneous urticaria (csu) |
2 |
|
chronic urticaria |
2 |
|
clinical article |
2 |
|
complement |
2 |
|
consensus |
2 |
|
consortium |
2 |
|
cost-effectiveness |
2 |
|
deficiency |
2 |
|
delabeling |
2 |
|
drug formulation |
2 |
|
drug hypersensitivity |
2 |
|
eczema |
2 |
|
effectiveness |
2 |
|
epidemiology < systemic lupus erythematosus |
2 |
|
equity |
2 |
|
excipient allergy |
2 |
|
hereditary |
2 |
|
hesitancy |
2 |
|
human papilloma virus |
2 |
|
immunoglobulin therapy |
2 |
|
influenza |
2 |
|
long-term prophylaxis |
2 |
|
mas-related g-protein coupled receptor-x2 (mrgprx2) |
2 |
|
mrgprx2 |
2 |
|
multidrug resistance |
2 |
|
non-allergist |
2 |
|
openness |
2 |
|
perioperative |
2 |
|
peritoneal dialysis |
2 |
|
peritonitis |
2 |
|
phenotype |
2 |
|
pneumococcal |
2 |
|
polymorphism, single nucleotide |
2 |
|
primary antibody deficiency |
2 |
|
protocol |
2 |
|
provocation |
2 |
|
reproducibility |
2 |
|
research practices |
2 |
|
secondary antibody deficiency |
2 |
|
sf-36v2 |
2 |
|
sleep |
2 |
|
small molecule antagonist |
2 |
|
spontaneous |
2 |
|
study design |
2 |
|
systemic lupus erythematosus - immunological aspects. |
2 |
|
transparency |
2 |
|
tryptase |
2 |
|
tyk2 kinase - genetics |
2 |
|
wpai |
2 |
|
β-lactam |
2 |
|
abdominal discomfort |
1 |
|
acare |
1 |
|
access |
1 |
|
advocacy |
1 |
|
allergist |
1 |
|
alliance |
1 |
|
androgens |
1 |
|
anergy |
1 |
|
antibodies |
1 |
|
antibody-dependent enhancement |
1 |
|
anxiety |
1 |
|
asia-pacific |
1 |
|
asia–pacific |
1 |
|
asthma |
1 |
|
awareness |
1 |
|
berotralstat |
1 |
|
big data |
1 |
|
biologics |
1 |
|
bradykinin |
1 |
|
bread |
1 |
|
burkholderia pseudomallei |
1 |
|
c1 esterase inhibitor |
1 |
|
care |
1 |
|
cd4 |
1 |
|
challenge |
1 |
|
china |
1 |
|
climate change |
1 |
|
cofactor |
1 |
|
contrast media |
1 |
|
control |
1 |
|
corticosteroid |
1 |
|
covid-19 vaccine |
1 |
|
covid-19 vaccines |
1 |
|
covid19 |
1 |
|
csu |
1 |
|
delabelling |
1 |
|
dermatology |
1 |
|
drugs |
1 |
|
endoscopy |
1 |
|
excipient |
1 |
|
exercise-induced |
1 |
|
exposome |
1 |
|
factor xii |
1 |
|
factor xiia |
1 |
|
fatigue |
1 |
|
food |
1 |
|
food allergy |
1 |
|
food-dependent |
1 |
|
function |
1 |
|
genome |
1 |
|
greater bay area |
1 |
|
hae |
1 |
|
hae-c1inh |
1 |
|
hae-nc1inh |
1 |
|
health disparities |
1 |
|
health-related quality of life |
1 |
|
health-related quality of life (hr-qol) |
1 |
|
helper t cell |
1 |
|
hives |
1 |
|
house dust mite |
1 |
|
icatibant |
1 |
|
immunology |
1 |
|
intradermal test |
1 |
|
level |
1 |
|
low-risk |
1 |
|
lymphocytes |
1 |
|
macau |
1 |
|
melioidosis |
1 |
|
microbiota |
1 |
|
monoclonal antibody |
1 |
|
mycotic aneurysms |
1 |
|
nonallergist |
1 |
|
olfactory |
1 |
|
olfactory dysfunction |
1 |
|
omega-5-gliadin |
1 |
|
opioid |
1 |
|
original antigenic sin |
1 |
|
pathophysiology |
1 |
|
pathway |
1 |
|
patient support groups |
1 |
|
period |
1 |
|
pharmacists |
1 |
|
pharmacogenetics |
1 |
|
pollution |
1 |
|
protocols & guidelines |
1 |
|
pyroglyphidae |
1 |
|
questionnaire |
1 |
|
referral |
1 |
|
refractory |
1 |
|
registry |
1 |
|
regulatory aspects |
1 |
|
sars-cov-2 variants |
1 |
|
screening |
1 |
|
skin prick test |
1 |
|
skin test |
1 |
|
skin testing |
1 |
|
skin tests |
1 |
|
smell |
1 |
|
steroid |
1 |
|
sublingual immunotherapy |
1 |
|
testing |
1 |
|
treatment |
1 |
|
type 2 hae |
1 |
|
utility |
1 |
|
wheat |
1 |
|
wheat allergy |
1 |
|
wheat-dependent exercise-induced anaphylaxis |
1 |
